BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28750493)

  • 1. Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose/positron-emission tomography in advanced Hodgkin lymphoma.
    Biggi A; Bergesio F; Chauvie S; Bianchi A; Menga M; Fallanca F; Hutchings M; Gregianin M; Meignan M; Gallamini A
    Q J Nucl Med Mol Imaging; 2021 Dec; 65(4):410-415. PubMed ID: 28750493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma.
    Santos FM; Marin JFG; Lima MS; Silva-Junior WF; Alves LBO; Moreira FR; Velasques RD; Atanazio MJ; Maia ACA; Buchpiguel CA; Buccheri V; Rocha V
    Ann Hematol; 2024 Jan; 103(1):175-183. PubMed ID: 37796339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim FDG
    Duarte S; Roque A; Saraiva T; Afonso C; Marques BA; Lima CB; Neves D; Lai AC; Costa G; Cipriano A; Geraldes C; Ruzickova L; Carda JP; Gomes M
    Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e107-e116. PubMed ID: 36567213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
    Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interobserver variability in interim PET assessment in Hodgkin lymphoma-reasons and solutions.
    Georgi TW; Kurch L; Hasenclever D; Warbey VS; Pike L; Radford J; Sabri O; Kluge R; Barrington SF
    PLoS One; 2023; 18(3):e0283694. PubMed ID: 36976821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.
    Gallamini A; Barrington SF; Biggi A; Chauvie S; Kostakoglu L; Gregianin M; Meignan M; Mikhaeel GN; Loft A; Zaucha JM; Seymour JF; Hofman MS; Rigacci L; Pulsoni A; Coleman M; Dann EJ; Trentin L; Casasnovas O; Rusconi C; Brice P; Bolis S; Viviani S; Salvi F; Luminari S; Hutchings M
    Haematologica; 2014 Jun; 99(6):1107-13. PubMed ID: 24658820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
    Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
    J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic evaluation value of (18)F-FDG PET-CT in Hodgkin's lymphoma after treatment].
    Wan H; Liu P; Liang Y; Jiang SY; Lyu L; Zhang ZW; Wu N; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1275-1281. PubMed ID: 34915636
    [No Abstract]   [Full Text] [Related]  

  • 9. Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment.
    Ferrari C; Niccoli Asabella A; Merenda N; Altini C; Fanelli M; Muggeo P; De Leonardis F; Perillo T; Santoro N; Rubini G
    Medicine (Baltimore); 2017 Feb; 96(5):e5973. PubMed ID: 28151888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT.
    Jorgov L; Montravers F; Balogova S; Ragu C; Pacquement H; Leblanc T; Abbou S; Ducou-Lepointe H; Landman-Parker J; Talbot JN
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1220-30. PubMed ID: 26660144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy.
    Hoppe BS; McCarten KM; Pei Q; Kessel S; Alazraki A; Mhlanga JC; Lai HA; Eutsler E; Hodgson DC; Roberts KB; Charpentier AM; Keller FG; Voss SD; Wu Y; Cho SY; Kelly KM; Castellino SM
    Int J Radiat Oncol Biol Phys; 2023 Aug; 116(5):1025-1030. PubMed ID: 36868525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma.
    Li X; Sun X; Li J; Liu Z; Mi M; Zhu F; Wu G; Lan X; Zhang L
    Cancer Med; 2019 Sep; 8(11):5012-5022. PubMed ID: 31293092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma.
    Al-Ibraheem A; Anwer F; Juweid ME; Shagera QA; Khalaf AN; Obeidat S; Mansour A; Ma'koseh M; Halahleh K; Jaradat I; Almasri N; Mansour A
    Sci Rep; 2022 Oct; 12(1):17702. PubMed ID: 36271128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
    Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
    Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semiquantitative analysis of interim
    Ribeiro T; Marques A; Ferreira G; Castro C; Tavares M; Espírito-Santo A; Moreira C; Mariz J
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(5):281-286. PubMed ID: 34425968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET).
    Annunziata S; Cuccaro A; Calcagni ML; Hohaus S; Giordano A; Rufini V
    Ann Nucl Med; 2016 Oct; 30(8):588-92. PubMed ID: 27246952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of imaging markers from 18FDG-PET/CT in paediatric patients with Hodgkin lymphoma.
    Rodríguez Taroco MG; Cuña EG; Pages C; Schelotto M; González-Sprinberg GA; Castillo LA; Alonso O
    Nucl Med Commun; 2021 Mar; 42(3):306-314. PubMed ID: 33306628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value on advance hodgkin lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial.
    Biggi A; Chauvie S; Fallanca F; Guerra L; Bergesio F; Menga M; Bianchi A; Gregianin M; Chiaravalloti A; Schillaci O; Pavoni C; Patti C; Picardi M; Romano A; Schiavotto C; Sorasio R; Viviani S; La Nasa G; Trentin L; Rambaldi A; Gallamini A
    Hematol Oncol; 2023 Aug; 41(3):415-423. PubMed ID: 36534947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and prognostic role of interim 18F-FDG PET/CT in elderly Hodgkin lymphoma: a dual-center experience.
    Albano D; Mazzoletti A; Zilioli VR; Muzi C; Crucitti L; Tucci A; Pagani C; Re A; Rossetti C; Giubbini R; Bertagna F
    Leuk Lymphoma; 2020 Dec; 61(13):3209-3216. PubMed ID: 32705908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma--results for dedicated assessment criteria in a blinded dual-centre read.
    Furth C; Amthauer H; Hautzel H; Steffen IG; Ruf J; Schiefer J; Schönberger S; Henze G; Grandt R; Hundsdoerfer P; Dietlein M; Kobe C
    Ann Oncol; 2011 May; 22(5):1198-1203. PubMed ID: 20966182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.